Advanced ovarian clear cell carcinoma with RAD50 mutation treated by PARP inhibitor pamiparib combined with anti-angiogenesis therapy: a case report

Ovarian clear cell carcinoma (OCCC) is a relatively uncommon epithelial ovarian malignancy with unique clinical, histopathologic and genetic characteristics. Patients with advanced OCCC have poor outcomes and are resistant to standard chemotherapy. Targeted therapy offers a novel approach for treating OCCC. We report the case of a 45-year-old female patient with advanced OCCC who experienced relapse after standard treatment. Further, a frameshift mutation in the homologous recombination repair-related gene RAD50 (RAD50-p.I371Ffs*8) was identified by genetic testing. Next, the patient had received targeted combination therapy with poly (ADP-ribose) polymerase (PARP) inhibitor pamiparib and bevacizumab, achieving partial remission. Patient's symptoms improved significantly compared to before. To date, the patient has been followed up for more than half a year with favorable survival and high quality of life. The case report suggested that parmiparib-targeted therapy is a viable treatment option for advanced OCCC patients with RAD50 mutation.

 

Comments:

Thank you for sharing the case report. It seems that the patient in question, a 45-year-old female with advanced ovarian clear cell carcinoma (OCCC), experienced relapse after standard treatment. However, genetic testing revealed a frameshift mutation in the RAD50 gene, which is involved in homologous recombination repair.

Given the poor outcomes and resistance to standard chemotherapy in advanced OCCC, targeted therapy was pursued as an alternative approach. The patient received a combination of a poly (ADP-ribose) polymerase (PARP) inhibitor called pamiparib and bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor (VEGF).

The treatment regimen resulted in partial remission for the patient, with significant improvement in symptoms compared to before. Additionally, the patient has been followed up for more than half a year, showing favorable survival and a high quality of life.

This case report suggests that targeted therapy with pamiparib may be a viable treatment option for advanced OCCC patients with a RAD50 mutation. It highlights the potential of PARP inhibitors in combination with other agents, such as bevacizumab, in improving outcomes for patients with this specific subtype of ovarian cancer.

It's important to note that this case report represents an individual patient's experience, and treatment decisions should be made based on comprehensive evaluation and consultation with a healthcare professional who can consider the specific characteristics of each patient and the available treatment options.
 

Related Products

Cat.No.	Product Name	Information
S8592	Pamiparib	Pamiparib is a potent and selective inhibitor of PARP1 and PARP2 with IC50 values of 0.83 and 0.11 nM, respectively in biochemical assays. It shows high selectivity over other PARP enzymes.

Related Targets

PARP